A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: Safety and efficacy - 08/08/11
Abstract |
Background |
Treating multiple upper facial rhytids at one time is common, but has not been researched extensively.
Objective |
We sought to compare the safety, efficacy, and effect duration of 3 botulinum neurotoxin type A (BoNTA) doses in treating multiple upper facial rhytids.
Method |
Sixty women, randomized to 32, 64, or 96 U total doses, were assessed at baseline, week 2, week 4, then every 4 weeks. The primary efficacy measure was proportion of responders on the patient global assessment of improvement. Adverse events (AEs) were monitored.
Results |
All BoNTA doses were effective and safe. Significant between-group differences occurred in the percentage of responders (96 U: 71%, 64 U: 61%, 32 U: 26%; P = .0007). Adverse events did not differ significantly among groups; no serious treatment-related adverse events occurred.
Limitations |
BoNTA doses were fixed and not tailored to individuals.
Conclusion |
These results confirm the efficacy and safety of 3 doses of BoNTA for treating upper facial rhytids in female patients; higher doses afforded greater benefit.
Le texte complet de cet article est disponible en PDF.Abbreviations used : AE, BoNTA, FWS, PGA, TOGA
Plan
Supported by a grant from Allergan Inc, Irvine, California. |
|
Disclosure: Drs Carruthers and Carruthers are consultants and investigators for and receive honoraria from Allergan Inc, which sponsored the study and the preparation of the article. They are also consultants and investigators for Merz GmbH and Solstice Neurosciences Inc. |
Vol 60 - N° 6
P. 972-979 - juin 2009 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?